Galectin Therapeutics Inc. (NASDAQ: GALT) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Galectin Therapeutics Inc. (NASDAQ: GALT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update
Galectin Therapeutics Appoints Khurram Jamil, M.D. to Chief Medical Officer [Yahoo! Finance]